s
News
VODIS’ TENANT HAS PASSED THE WASHINGTON STATE LIQUOR AND CANNABIS BOARD’S TRACEABILITY TEST

2015-08-31 0500 PT - News Release

VP Close 2015-08-28 C$ 0.12

 Mr. Otto Folprecht reports

 VODIS’ TENANT HAS PASSED THE WASHINGTON STATE LIQUOR AND CANNABIS BOARD’S TRACEABILITY TEST

 August 31, 2015- Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV /Q:VDQSF) (“Vodis” or “the Company”) is pleased that its i-502 tenant has passed all of the 27 components of the required traceability test.

The Company’s tenant has received notification from the Washington State Liquor and Cannabis Board (WSLCB) that it has passed the last requirement prior to an inspection.   The tenant has notified the WSLCB of its readiness for an inspection.

Otto Folprecht, Vodis’ Chief Executive Officer, commented: “The Company is extremely pleased with the high level of proficiency of its i-502 client in mastering the complex traceability requirements mandated by Washington State. Following an inspection by the WSLCB, Vodis’ client will move forward to becoming a Washington State marijuana producer and processor at our Bellingham facility.”

 About Vodis

Vodis is one of Canada’s foremost brand names in the medical marijuana business. Its master grow teams have consistently won or placed at each competition they have entered with their “VIP” brand. The Company, with facilities in BC and Washington State, is also actively looking into expansion opportunities in other countries and US states.

 For further information please contact:

 Richard Schnoor

Head of Corporate Communications

Vodis Pharmaceuticals Inc.

8788 River Road

Delta, BC V4G 1B5

Direct: 1-866-210-1420 ext. 110

Web: www.vodis.ca

 

While Vodis Pharmaceuticals and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed the Vodis brand quality standards.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

 Forward-Looking Information:

 This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. All of the forward-looking statements made in this news release and any accompanying graphic links are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

 

 




Vodis Corporate

  • Page 1 of 61